knowledge -WSS

knowledge

author：comprehensive 2025-10-02 21:07:32 - browse：6

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： 'A game

focus

WSS

'A game

Is there really a nursing shortage in the U.S.?

Eli Lilly CEO gives to Mike Pence presidential super PAC

Assistant physicians can help address the primary care shortage

Health tech investors get more selective as pandemic boom fades

UnitedHealth, Optum discontinue NaviHealth name

entertainment

knowledge

knowledge

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

UnitedHealth, Optum discontinue NaviHealth name

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Neurocrine congenital adrenal hyperplasia trial succeeds

State Dept. review finds Biden bears some blame for Afghanistan failures

STAT Readout: Friday, Oct. 20 biotech updates

How to save PrEP access — and even expand it

Health tech investors get more selective as pandemic boom fades

Tori Bowie and the unacceptable rates of Black maternal death

Assistant physicians can help address the primary care shortage

leisure time

STAT Readout Newsletter: Biotech news today

Why the quest to eradicate polio has stumbled

Assistant physicians can help address the primary care shortage

FDA clears Verve to begin U.S. study of gene

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Questions loom on AstraZeneca cancer drug as safety concerns ebb

focus

leisure time

focus

knowledge